OBJECTIVE

2

To compare the effect between drug donation model and national drug negotiated model on drug sales， and to provide reference for pharmaceutical enterprises to optimize their business strategies.

METHODS

2

Based on medical insurance statistics and settlement data of city A in Jiangsu province from 2013 to 2018， trastuzumab was selected as the representative drug. The sales and utilization of trastuzumab were compared during the implementation of the two models. At the same time， the changes of medication behavior of some patients were analyzed.

RESULTS

2

After the implementation of drug donation model， sales volume and turnover of trastuzumab increase by 193.87% and 155.71% in that year compared with the previous year， and then the growth trend became stable； after including the national negotiated drug list， the number of users of trastuzumab in the year increased by 87.68% compared with the previous year， and the sales volume increased by 48.06%； turnover increased by 22.81% even though the unit price decreased significantly. Both models could improve drug sales， and the results of multiple linear regression also proved that different models had a significant impact on the consumption sum of trastuzumab in patients.

CONCLUSIONS

2

Under the condition that the unit price level of drugs is approximately the same， both drug donation model and national drug negotiated model can increase the sales volume and expand the coverage of drugs. The latter reduces the drug threshold of patients， and plays a positive role in improving the drug accessibility of patients and the sales and development of enterprises.